WO1993005805A1 - Emulsion containing parathyroid hormone for pernasal administration - Google Patents
Emulsion containing parathyroid hormone for pernasal administration Download PDFInfo
- Publication number
- WO1993005805A1 WO1993005805A1 PCT/JP1992/001179 JP9201179W WO9305805A1 WO 1993005805 A1 WO1993005805 A1 WO 1993005805A1 JP 9201179 W JP9201179 W JP 9201179W WO 9305805 A1 WO9305805 A1 WO 9305805A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion
- pth
- administration
- white
- acid
- Prior art date
Links
- 239000000839 emulsion Substances 0.000 title claims abstract description 70
- 239000000199 parathyroid hormone Substances 0.000 title claims abstract description 43
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 37
- 102000003982 Parathyroid hormone Human genes 0.000 title claims abstract description 29
- 229960001319 parathyroid hormone Drugs 0.000 title claims abstract description 26
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 15
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 15
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 15
- 150000003976 azacycloalkanes Chemical class 0.000 claims abstract description 14
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 12
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 238000010521 absorption reaction Methods 0.000 claims description 22
- -1 decylthio Chemical group 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000003623 enhancer Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- VDPRSOCKHVPZRS-UHFFFAOYSA-N 1-(2-decylsulfanylethyl)pyrrolidin-2-one Chemical compound CCCCCCCCCCSCCN1CCCC1=O VDPRSOCKHVPZRS-UHFFFAOYSA-N 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 27
- 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000000203 mixture Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000004945 emulsification Methods 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
- 229940074774 glycyrrhizinate Drugs 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 108010049264 Teriparatide Proteins 0.000 description 9
- 239000003995 emulsifying agent Substances 0.000 description 9
- BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 description 9
- 229960000338 teriparatide acetate Drugs 0.000 description 9
- 102100036893 Parathyroid hormone Human genes 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000001804 emulsifying effect Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- ZYVYEJXMYBUCMN-UHFFFAOYSA-N 1-methoxy-2-methylpropane Chemical group COCC(C)C ZYVYEJXMYBUCMN-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920001393 Crofelemer Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N pentanal Chemical compound CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- KNNLWVUFUIAFJW-UHFFFAOYSA-N propyl benzenecarboperoxoate Chemical compound CCCOOC(=O)C1=CC=CC=C1 KNNLWVUFUIAFJW-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- VMSNAUAEKXEYGP-YEUHZSMFSA-M sodium glycodeoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 VMSNAUAEKXEYGP-YEUHZSMFSA-M 0.000 description 1
- WRZYGPIFICWRCG-OOFFSTKBSA-M sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trih Chemical compound [Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WRZYGPIFICWRCG-OOFFSTKBSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PAFMAHIOSMYVGN-UHFFFAOYSA-N trisodium trinitrate Chemical compound [Na+].[Na+].[Na+].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PAFMAHIOSMYVGN-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention relates to an emulsion for nasal administration containing parathyroid hormone (PTH) as an active ingredient, and in particular, has excellent emulsion stability and is safe and efficient by spraying into the nasal cavity. And the nasal emulsion improved to absorb P ⁇ Hs.
- PTH parathyroid hormone
- Bioactive peptides are becoming one of the fastest-growing areas of future drug therapy.
- the current route of administration of peptide drugs is mostly limited to injections, and it is simpler and more self-reliant, especially in the treatment of chronic diseases, in order to reduce the hassle of visiting hospitals and reducing pain and pain at the injection site.
- JP-A-63-29332 a method of intranasal administration of polypeptides using M-juic acid such as cholic acid, deoxycholic acid, and taurocholic acid is known (JP-A-63-29332).
- M-juic acid such as cholic acid, deoxycholic acid, and taurocholic acid
- bioactive peptides and water-absorbable Also known is a powder transdermal administration agent comprising a poorly soluble base (Japanese Patent Application Laid-Open No. 60-224646).
- formulations using these are not sufficient in terms of absorption or local irritation, and have not yet been put to practical use.
- PTHs are generally known as peptideformone having a serum calcium-elevating action, and are used for diagnosis of hypoparaparathyroidism and the like.
- PTHs are highly hydrophilic and have high molecular weight (about 4,000 to 10,000) peptides, and are extremely difficult to absorb from the digestive tract.
- Japanese Patent Application Laid-Open No. 62-238628 describes that an azacycline aldehyde derivative has an excellent absorption promoting action. It has been revealed that the derivative has a very different absorption promoting action from that of the above-mentioned conventional nasal administration agent in physical properties, and has a very strong absorption promoting action. Therefore, this was used as an absorption enhancer to produce PTH nasal agents, but the azacycloalkene derivative was an oily substance, which needed to be emulsified, which was necessary for the emulsification. The conventional emulsifiers were insufficient and satisfactory ones could not be obtained.
- Emulsifiers commonly used in fat emulsions for intravenous injection include egg yolk lecithin and soy lecithin, which have poor stability at room temperature and are not uniform. There are many problems with sex.
- the present invention has been made in view of the above-mentioned problems, and provides an emulsion preparation having good stability when an azacycloalnic acid derivative is used as an absorption enhancer in a parenteral administration of PTHs. It is intended for that purpose.
- the present inventors have studied emulsifiers suitable for the above emulsion formulation and concluded.
- the present invention comprises a PTH as an active ingredient and at least an absorption enhancer represented by the following general formula (1):
- R represents an alkyl group
- m represents an integer of 2 to 4
- n represents an integer of 1 to 15.
- ⁇ represents 1 to 3
- R represents an alkenyl group having 5 to 11 carbon atoms.
- the present invention relates to an emulsion for transdermal administration containing a frequently used azacycloalkane derivative represented by-), glycyrrhizic acid or a nontoxic salt thereof, and appropriate water.
- the active ingredient of the present invention is It has an amino acid sequence of 84, and natural PTH or an analog thereof is known.
- human ⁇ ⁇ ⁇ ⁇ (1 ⁇ — PTH) (1-8 4) [Biochemistry 17, 5 72 3 (1978)]
- h—PTH (1 — 38) [Tokusho 5 7 — 8 14 No. 48 publication]
- ⁇ - ⁇ ⁇ ⁇ (1-3) [Hoppe Seyler's Z. Physiol.
- rat — PTH (1-3) [Endocrinol., 1 1 7 (3), 1 230 (1 985)), ⁇ -PTH (1-8) [Am. J. Med., 50, 639 (1 971)], ⁇ PTH (1-3.4), ⁇ PTH (1-34) NH 2 [Pthobiology annual 11, 5 3 (1981)] and the like, Preferably, it is h-PTH (1-34) having a 34 amino acid sequence with a molecular weight of about 4,400.
- concentration of PTHs in the emulsion for nasal administration of PTHs according to the present invention is usually 10 to 100 units per 1 m 1 of the preparation, more preferably 100 to 100 units, more preferably 100 to 100 units. Is a unit. .
- the azacycloalkane derivative used as an absorption enhancer in the present invention is an oily substance, which is represented by the above general formula [1], and is disclosed in Japanese Patent Application Laid-Open No. Sho 62-238628. Has been described. 'R in the general formula (1) will be more specifically described.
- An alkyl group is methyl, techinole, furobinole, butyle, pentinole, hexyl, heptyl, octyl, nonyl, decyl, ⁇ decyl, dodecyl, tridecyl, It is a linear or branched alkyl group such as tetradecyl, pentadecyl, hexadecyl, heptadecyl, otatadecyl, nonadecyl, and eicosyl.
- the most preferred absorption promoter is 1- [2— (decylthio) wherein R in the general formula [1] is a linear alkyl group having 10 carbon atoms, m is S, and ⁇ is 2. ) Ethyl] azacyclopentane-2-one (oil).
- the amount of the azacycloalkane derivative to be added is 0.01% to 10% (WZV) concentration, preferably 0.1% to 5% ( ⁇ NO) concentration in the preparation. Puru.
- glycyrrhizic acid or a non-toxic salt thereof used in the present invention is known as a component extracted from natural licorice, and is widely used as a cosmetic or a sweetener in food additives.
- glycyrrhizic acid or non-toxic salts thereof include glycyrrhizic acid, diglyceryl glycyrrhizinate, monoglycyrrhizic acid ammonium, sodium glycyrrhizinate, and glycyrrhizic acid.
- examples thereof include trisodium trinitrate, and particularly preferred is glycyrrhizic acid diammonium.
- the amount of the above-mentioned dalicyllithic acid or a non-toxic salt thereof may be 0.1% or more in the preparation, and is usually 0.1% to 5% (W / V) in the preparation, more preferably. Is a 0.5% to 2% (W / V) concentration.
- the appropriate amount of water in the present invention refers to the above-mentioned active ingredient of the present invention, such as ⁇ ⁇ , an azacycloalkane derivative as an absorption enhancer, and glycyrrhizic acid or a nontoxic salt thereof as an emulsifier. It is an appropriate amount as the remaining amount when the concentration is adjusted.
- nasal preparations are aqueous liquids generally suitable for spraying or dropping.
- the emulsion of the present invention uses an appropriate amount of water so that at least the azacycloalkane derivative and the glycyrrhizic acid or a nontoxic salt thereof, which are the above-mentioned oily substances, have the above-mentioned formulation concentrations.
- the emulsion referred to in the present invention is a microscopic emulsion obtained by using the above-mentioned oily azacycloalkane derivative and water. It means a liquid that is milky white and colorless and transparent when homogeneous. And the PH from 5?
- the osmotic pressure ratio to physiological saline is preferably adjusted to around 1.
- Buffer thorns such as acetic acid, lactic acid, citric acid, phosphate buffers, etc. can be added.
- daricerin is preferable as a tonicity agent, and other additives such as sodium chloride, sodium chloride, mannitol, and glucose can be added as needed.
- Preservatives may be added to the emulsion for transdermal administration, and preservatives which are therapeutically acceptable are generally used.
- preservatives which are therapeutically acceptable are generally used.
- paraoxybenzoic acid esters chlorobutanol / phenylethyl alcohol, benzolconidum chloride, phenol, thimerosal, dehydroacetic acid, sorbic acid and the like can be mentioned.
- Appropriate preservative concentrations vary somewhat depending on the type of preservative selected, but are generally between 0.02% and 2% (W / V).
- a transdermal emulsion it can be produced by mixing and emulsifying the components in an arbitrary order according to a method known per se.
- dicalium glycyrrhizinate, h-PTH (1-34) and the above-mentioned additives according to the present invention are added with an appropriate amount of distilled water for injection, heated and stirred. After dissolution, adjust the pH to the specified value by adding a pH adjuster such as sodium hydroxide or hydrochloric acid. After the addition of the azacycloalkane derivative, which is an absorption enhancer, the mixture can be emulsified by an ordinary method using an emulsifier.
- H-PTH 1-34
- H-PTH 1-34
- the homogeneous emulsion preparation containing h-PTH (1-34) obtained by emulsification is sterile-filtered by a 0.22 ytm membrane filter, for example, and filled into a vial, for example. Or a lyophilized formulation as appropriate.
- the dose of the emulsion of the present invention varies depending on the purpose of administration.
- a person can use a metering sprayer (0.05 to 0.1 ml / stroke) once or twice a day for 1 to 2 times.
- a metering sprayer 0.05 to 0.1 ml / stroke
- it can be administered reliably by spraying both nostrils.
- the emulsion of the present invention for administration of P-type pharmaceuticals is usually administered in the form of a mist by a spray atomizer into the cavity for the purpose of systemic action.
- the preparation of the present invention can surely penetrate mucous membranes and spread PTHs throughout the body by being adhered to a wide area of the nasal membrane. Therefore, the emulsion for administration of PTH compounds according to the present invention has no problems such as pain and pain due to injection administration to patients having a disease to be administered with PTH compounds, and can be self-administered.
- FIG. 1 shows the time course of the mean h-PTH (1-3) plasma concentration in rats after intranasal administration and intramuscular administration of the preparation of the present invention and the control preparation.
- turbidity which is an indicator of emulsifying power
- HCO-60 and Tween-80 concentration of diglyceryl glycinate was lower and the emulsifying power was stronger. From these results, diglyceryl glycyrrhizinate has remarkably superior emulsifying power and emulsion stability compared to HC 0-60 and Tween 80, which are widely used as pharmaceutical additives. I understood that.
- 0.1 to 1.0 I.O. white transparent (state in which the back can be seen through) 1.0 to white emulsification Table 2, when using 80, i pjsqj 3 ⁇ 4 3 ⁇ 4 ⁇ IS. ⁇ 3 ⁇ 43 ⁇ 4 Turbidity after standing for 3 days
- An emulsion for use with a PTH compound of the present invention was obtained by the following preparation. Occasionally, add methyl baloxybenzoate and baloxy to distilled water. To 80 ml of a paraben solution prepared by dissolving propyl benzoate, 2.2 g of glycerin and 1 g of dicalium glycyrrhizinate were added and dissolved by stirring. (Decylthio) ethyl] azacyclopentane —2-one, add lg, adjust the pH to 5.5 with 1N sodium hydroxide, and adjust the total amount to 100 ml with the above paraben solution.
- h-PTH (1-34) (specific activity 3> 300 units Zmg *; teriparatide acetate; manufactured by Toyo Brewery Co., Ltd.) 0.607 mg of the emulsion obtained above was added to 10 ml. To give a composition having the following composition.
- the homogenate is centrifuged at 150 XG for 10 minutes, and the supernatant is further centrifuged at 220 XG for 15 minutes. Discard the supernatant, suspend the emulsion in the upper layer of the precipitate in solution A, wash this suspension by centrifugation at 2500 XG for 15 minutes, resuspend and disperse in a container. Note, freeze at -70 and store at -20.
- Thaw the PTH receptor preparation stored at 20 ° C at room temperature add creatine kinase previously dissolved in solution A, and add creatine kinase 0.1 mg ZmI and PTH receptor in solution A.
- Prepared protein amount 1. Prepare 4 mg gZm 1 and keep on ice. After placing the above sample solution in a 37 ° C constant temperature bath for several minutes, add the above PTH receptor creatine kinase solution by 50 u1 each, and incubate at 37 ° C for 10 minutes. I do. Then, add 100 ⁇ l of 0.1 M acetate buffer (pH 4.0), immediately put on ice, and immediately heat the test tube with boiling water for 1 minute to stop the reaction.
- 0.1 M acetate buffer pH 4.0
- the reaction stopped sample of the above 3 is diluted 10 to 30 times with distilled water, and G. Deproteinize by centrifugation for 15 minutes. Measure the amount of C-ATP in the supernatant using an RIA kit (Yamasa Oil Co., Ltd.).
- the activity of teriparatide acetate is measured by a biological assay using rat renal cortical cell membranes based on teriparatide acetate standards, and is expressed in units of teriparatide acetate.
- the unit of teriparatide acetate is the standard parathyroid hormone (1-84) (200 international unit noamples provided by WH 0; WH 067/3) by the measurement method shown above.
- the relative activity of the standard teriparatide acetate was determined on the basis of 4 2) to be 3300 units Zmg, indicating that this standard teriparatide acetate was 3300 units of teriparatide acetate It is expressed as g.
- a nasal comparative solution containing PTHs having no 1- [2- (decylthio) ethyl] azacyclopentan-2-one was obtained by the following preparation.
- h-PTH. (1-34) (specific activity 3300 units / mg) 0.607 mg was dissolved in 10 ml of the emulsion obtained above, and A composition comprising the composition was obtained.
- ⁇ ⁇ 1 volume of distilled water for injection was 1 ml.
- FIG. 1 shows the blood h—PTH (1—34) concentration after administration of the above preparation A and control preparation B 01 ⁇ (20 units / kg).
- Blood h-PTH (1-34) concentrations after intramuscular administration (10 units Zkg) were also shown.
- the preparation containing 1% of [1- [2- (decylthio) ethyl] azacyclopentane-12-one] obtained in the present invention is clearly more h-PTH (1-3) as compared with the control preparation B. It showed excellent absorption, and showed an absorption rate of 37% compared to the blood concentration-time area (AUC) in intramuscular injection.
- AUC blood concentration-time area
- FIG. 1 shows the results when h-PTH (1-34) (lOUZkg) was intramuscularly administered as a control, and (a) shows the results of Experimental Example 3.
- (A) shows the results of intranasal administration of the preparation A obtained in (a), and ( ⁇ ) shows the results of the onset administration of the control preparation B obtained in (b) of Experimental Example 3. It is shown.
- Preferred examples of the PTH emulsion for transdermal administration of the present invention are as follows. .
- the final formulation was obtained by filtering the obtained emulsion through a 0.22 ⁇ m membrane filter and aseptically filling vials for nasal administration.
- Example 2
- the final emulsion was obtained by filtering the obtained emulsion with a 0.22 / m membrane filter and filling the vial for transdermal administration aseptically.
- the final formulation was obtained by filtering the obtained emulsion through a 0.22 m membrane filter and aseptically filling vials for nasal administration.
- an azacycloalkane derivative as an absorption enhancer improves the absorbability of the emulsion for administration of PTH analogs provided by the present invention, and at that time, glycyrrhizic acid or a non-toxic salt thereof is added.
- glycyrrhizic acid or a non-toxic salt thereof is added.
- a uniform and stable emulsion could be obtained.
- the obtained emulsion was less harmful to the nasal mucosa than the conventional transdermal drug administration, was excellent in absorption from the nasal mucosa, and showed good bioavailability. Therefore, the present invention makes it possible to commercialize emulsions for nasal administration of PTHs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/211,035 US5407911A (en) | 1991-09-17 | 1992-09-16 | Parathyroid hormone-containing emulsion for nasal administration |
DE69226370T DE69226370T2 (de) | 1991-09-17 | 1992-09-16 | Parathyroidhormon enthaltene emulsion zur nasalen verabreichung |
KR1019940700867A KR0129865B1 (ko) | 1991-09-17 | 1992-09-16 | 파라티로이드 호르몬류 함유 경비 투여용 유제 |
AU25843/92A AU662168B2 (en) | 1991-09-17 | 1992-09-16 | Emulsion containing parathyroid hormone for pernasal administration |
CA002118655A CA2118655C (en) | 1991-09-17 | 1992-09-16 | Parathyroid hormone-containing emulsion for nasal administration |
EP92919966A EP0610502B1 (en) | 1991-09-17 | 1992-09-16 | Emulsion containing parathyroid hormone for pernasal administration |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3/236193 | 1991-09-17 | ||
JP03236193A JP3090353B2 (ja) | 1991-09-17 | 1991-09-17 | パラチロイドホルモン類含有経鼻投与用乳剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993005805A1 true WO1993005805A1 (en) | 1993-04-01 |
Family
ID=16997158
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1992/001179 WO1993005805A1 (en) | 1991-09-17 | 1992-09-16 | Emulsion containing parathyroid hormone for pernasal administration |
Country Status (9)
Country | Link |
---|---|
US (1) | US5407911A (ja) |
EP (1) | EP0610502B1 (ja) |
JP (1) | JP3090353B2 (ja) |
KR (1) | KR0129865B1 (ja) |
AT (1) | ATE168562T1 (ja) |
AU (1) | AU662168B2 (ja) |
CA (1) | CA2118655C (ja) |
DE (1) | DE69226370T2 (ja) |
WO (1) | WO1993005805A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948825A (en) * | 1993-04-19 | 1999-09-07 | Institute For Advanced Skin Research Inc. | Microemulsion preparation containing a slightly absorbable substance |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1255723B (it) * | 1992-10-09 | 1995-11-13 | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
ATE215377T1 (de) * | 1993-07-30 | 2002-04-15 | Teijin Ltd | Pulver zur nasalen verabreichung peptidischer oder proteinischer arzneistoffe |
US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
US6379688B2 (en) | 1997-02-28 | 2002-04-30 | Senju Pharmaceutical Co., Ltd. | Preservative for emulsion and emulsion containing same |
JP2000247911A (ja) | 1999-02-26 | 2000-09-12 | Hisamitsu Pharmaceut Co Inc | 大腸用吸収促進剤 |
US8580290B2 (en) * | 2001-05-08 | 2013-11-12 | The Board Of Regents Of The University Of Oklahoma | Heparosan-based biomaterials and coatings and methods of production and use thereof |
WO2003039331A2 (en) * | 2001-11-05 | 2003-05-15 | Eli Lilly And Company | Method for improving stability of a bone-connecting implant |
EP1380630A3 (en) * | 2002-07-11 | 2004-01-28 | Herbal Apothecary Limited | Hydrocarbon wetting and separation agent |
US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
US20060052306A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
US20060189533A1 (en) * | 2004-05-10 | 2006-08-24 | Nastech Pharmaceutical Company Inc. | Stable pharmaceutical dosage forms of teriparatide |
US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
US20080119408A1 (en) * | 2006-07-07 | 2008-05-22 | Nastech Pharmaceutical Company Inc. | Pth formulations for intranasal delivery |
EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
US9687559B2 (en) * | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
US9925209B2 (en) | 2008-03-19 | 2018-03-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same |
WO2013149161A1 (en) | 2012-03-30 | 2013-10-03 | Deangelis Paul L | High molecular weight heparosan polymers and methods of production and use thereof |
CA3101326C (en) * | 2018-10-29 | 2023-08-01 | Asahi Kasei Pharma Corporation | Method for preventing or treating osteoporosis, characterized by administering teriparatide or salt thereof at a frequency of twice a week |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62238261A (ja) * | 1986-04-08 | 1987-10-19 | Hisamitsu Pharmaceut Co Inc | アザシクロアルカン誘導体 |
JPH01233230A (ja) * | 1988-03-14 | 1989-09-19 | Minofuaagen Seiyaku Honpo:Goushi | 経粘膜吸収促進剤及びこれを用いた点鼻剤 |
JPH0228121A (ja) * | 1988-07-15 | 1990-01-30 | Minofuaagen Seiyaku Honpo:Goushi | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 |
JPH0446129A (ja) * | 1990-06-12 | 1992-02-17 | Asahi Chem Ind Co Ltd | 新規なリポソーム形成助剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
US5059587A (en) * | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
JP2911496B2 (ja) * | 1989-09-11 | 1999-06-23 | 帝國製薬株式会社 | 生理活性ポリペプチド含有高吸収性経膣剤 |
JPH078806B2 (ja) * | 1990-08-16 | 1995-02-01 | 旭化成工業株式会社 | カルシトニン類含有経鼻投与用乳剤 |
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
-
1991
- 1991-09-17 JP JP03236193A patent/JP3090353B2/ja not_active Expired - Lifetime
-
1992
- 1992-09-16 WO PCT/JP1992/001179 patent/WO1993005805A1/ja active IP Right Grant
- 1992-09-16 KR KR1019940700867A patent/KR0129865B1/ko not_active IP Right Cessation
- 1992-09-16 AT AT92919966T patent/ATE168562T1/de not_active IP Right Cessation
- 1992-09-16 AU AU25843/92A patent/AU662168B2/en not_active Ceased
- 1992-09-16 EP EP92919966A patent/EP0610502B1/en not_active Expired - Lifetime
- 1992-09-16 CA CA002118655A patent/CA2118655C/en not_active Expired - Fee Related
- 1992-09-16 DE DE69226370T patent/DE69226370T2/de not_active Expired - Fee Related
- 1992-09-16 US US08/211,035 patent/US5407911A/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62238261A (ja) * | 1986-04-08 | 1987-10-19 | Hisamitsu Pharmaceut Co Inc | アザシクロアルカン誘導体 |
JPH01233230A (ja) * | 1988-03-14 | 1989-09-19 | Minofuaagen Seiyaku Honpo:Goushi | 経粘膜吸収促進剤及びこれを用いた点鼻剤 |
JPH0228121A (ja) * | 1988-07-15 | 1990-01-30 | Minofuaagen Seiyaku Honpo:Goushi | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 |
JPH0446129A (ja) * | 1990-06-12 | 1992-02-17 | Asahi Chem Ind Co Ltd | 新規なリポソーム形成助剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948825A (en) * | 1993-04-19 | 1999-09-07 | Institute For Advanced Skin Research Inc. | Microemulsion preparation containing a slightly absorbable substance |
Also Published As
Publication number | Publication date |
---|---|
JP3090353B2 (ja) | 2000-09-18 |
AU2584392A (en) | 1993-04-27 |
EP0610502A4 (en) | 1996-02-28 |
EP0610502A1 (en) | 1994-08-17 |
DE69226370T2 (de) | 1999-04-22 |
ATE168562T1 (de) | 1998-08-15 |
DE69226370D1 (de) | 1998-08-27 |
CA2118655C (en) | 1997-08-19 |
JPH0570367A (ja) | 1993-03-23 |
AU662168B2 (en) | 1995-08-24 |
KR0129865B1 (ko) | 1998-04-09 |
US5407911A (en) | 1995-04-18 |
CA2118655A1 (en) | 1993-04-01 |
EP0610502B1 (en) | 1998-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1993005805A1 (en) | Emulsion containing parathyroid hormone for pernasal administration | |
AU2003238862B9 (en) | Formulations for amylin agonist peptides | |
US6410511B2 (en) | Formulations for amylin agonist peptides | |
JP4405666B2 (ja) | 安定化テリパラチド溶液剤 | |
US7144861B2 (en) | Stabilized teriparatide solutions | |
AU760609B2 (en) | Formulations for amylin agonist peptides | |
WO1997006813A1 (fr) | Preparation pour muqueuses a base de peptides a activite physiologique | |
SK119895A3 (en) | Pharmaceutical composition containing lipophilic drugs | |
JPS61194034A (ja) | 経鼻投与用粉末状組成物 | |
NO322244B1 (no) | Farmasoytisk blanding omfattende aktivt fragment av paratyroid hormon | |
CA2047903C (en) | Calcitonin-containing emulsion for nasal administration | |
JPH0228121A (ja) | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 | |
BG64668B1 (bg) | Фармацевтични състави на пептиди, притежаващи малка разтворимост във физиологична среда | |
JP3555961B2 (ja) | 安定なペプチド医薬組成物 | |
AU778208C (en) | GRF-containing lyophilized pharmaceutical compositions | |
JP3608802B2 (ja) | 安定なカルシトニン医薬組成物及びその製造法 | |
JP2009149684A (ja) | アミリン作動薬ペプチド用製剤 | |
MXPA00005655A (en) | Stabilized teriparatide solutions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2118655 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1992919966 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08211035 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992919966 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992919966 Country of ref document: EP |